154 related articles for article (PubMed ID: 9109500)
1. EGR-1, the reluctant suppression factor: EGR-1 is known to function in the regulation of growth, differentiation, and also has significant tumor suppressor activity and a mechanism involving the induction of TGF-beta1 is postulated to account for this suppressor activity.
Liu C; Calogero A; Ragona G; Adamson E; Mercola D
Crit Rev Oncog; 1996; 7(1-2):101-25. PubMed ID: 9109500
[TBL] [Abstract][Full Text] [Related]
2. Reciprocal modulation between Sp1 and Egr-1.
Huang RP; Fan Y; Ni Z; Mercola D; Adamson ED
J Cell Biochem; 1997 Sep; 66(4):489-99. PubMed ID: 9282327
[TBL] [Abstract][Full Text] [Related]
3. Suppression of v-sis-dependent transformation by the transcription factor, Egr-1.
Huang RP; Darland T; Okamura D; Mercola D; Adamson ED
Oncogene; 1994 May; 9(5):1367-77. PubMed ID: 8152797
[TBL] [Abstract][Full Text] [Related]
4. Egr-1 negatively regulates human tumor cell growth via the DNA-binding domain.
Huang RP; Liu C; Fan Y; Mercola D; Adamson ED
Cancer Res; 1995 Nov; 55(21):5054-62. PubMed ID: 7585551
[TBL] [Abstract][Full Text] [Related]
5. EGR-1 enhances tumor growth and modulates the effect of the Wilms' tumor 1 gene products on tumorigenicity.
Scharnhorst V; Menke AL; Attema J; Haneveld JK; Riteco N; van Steenbrugge GJ; van der Eb AJ; Jochemsen AG
Oncogene; 2000 Feb; 19(6):791-800. PubMed ID: 10698497
[TBL] [Abstract][Full Text] [Related]
6. Suppression of growth and transformation and induction of apoptosis by EGR-1.
Liu C; Rangnekar VM; Adamson E; Mercola D
Cancer Gene Ther; 1998; 5(1):3-28. PubMed ID: 9476963
[TBL] [Abstract][Full Text] [Related]
7. Transforming growth factor beta stimulation of biglycan gene expression is potentially mediated by sp1 binding factors.
Heegaard AM; Xie Z; Young MF; Nielsen KL
J Cell Biochem; 2004 Oct; 93(3):463-75. PubMed ID: 15372625
[TBL] [Abstract][Full Text] [Related]
8. TGF-beta1 acts as a tumor suppressor of human malignant keratinocytes independently of Smad 4 expression and ligand-induced G(1) arrest.
Paterson IC; Davies M; Stone A; Huntley S; Smith E; Pring M; Eveson JW; Robinson CM; Parkinson EK; Prime SS
Oncogene; 2002 Feb; 21(10):1616-24. PubMed ID: 11896591
[TBL] [Abstract][Full Text] [Related]
9. Coordinate expression and distinct DNA-binding characteristics of the four EGR-zinc finger proteins in Jurkat T lymphocytes.
Skerka C; Decker EL; Zipfel PF
Immunobiology; 1997 Dec; 198(1-3):179-91. PubMed ID: 9442390
[TBL] [Abstract][Full Text] [Related]
10. Egr-1 mediates transcriptional activation of IGF-II gene in response to hypoxia.
Bae SK; Bae MH; Ahn MY; Son MJ; Lee YM; Bae MK; Lee OH; Park BC; Kim KW
Cancer Res; 1999 Dec; 59(23):5989-94. PubMed ID: 10606246
[TBL] [Abstract][Full Text] [Related]
11. Stimulation of the murine type II transforming growth factor-beta receptor promoter by the transcription factor Egr-1.
Wilder PJ; Bernadt CT; Kim JH; Rizzino A
Mol Reprod Dev; 2002 Nov; 63(3):282-90. PubMed ID: 12237943
[TBL] [Abstract][Full Text] [Related]
12. Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene EGR-1, which results in the up-regulation of NAG-1, an antitumorigenic protein.
Baek SJ; Kim JS; Moore SM; Lee SH; Martinez J; Eling TE
Mol Pharmacol; 2005 Feb; 67(2):356-64. PubMed ID: 15509713
[TBL] [Abstract][Full Text] [Related]
13. The transcription factor E2F-1 modulates TGF-beta1 RNA expression in glial cells.
Thatikunta P; Raj GV; Kundu M; Khalili K; Amini S
Oncogene; 1997 Jun; 14(24):2959-69. PubMed ID: 9205103
[TBL] [Abstract][Full Text] [Related]
14. HTLV-I and HTLV-II tax trans-activate the human EGR-1 promoter through different cis-acting sequences.
Sakamoto KM; Nimer SD; Rosenblatt JD; Gasson JC
Oncogene; 1992 Nov; 7(11):2125-30. PubMed ID: 1359492
[TBL] [Abstract][Full Text] [Related]
15. Regulation of KLF5 involves the Sp1 transcription factor in human epithelial cells.
Chen C; Zhou Y; Zhou Z; Sun X; Otto KB; Uht RM; Dong JT
Gene; 2004 Apr; 330():133-42. PubMed ID: 15087132
[TBL] [Abstract][Full Text] [Related]
16. Decreased expression and activity of the immediate-early growth response (Egr-1) gene product during cellular senescence.
Meyyappan M; Wheaton K; Riabowol KT
J Cell Physiol; 1999 Apr; 179(1):29-39. PubMed ID: 10082129
[TBL] [Abstract][Full Text] [Related]
17. Molecular heterogeneity and function of EWS-WT1 fusion transcripts in desmoplastic small round cell tumors.
Liu J; Nau MM; Yeh JC; Allegra CJ; Chu E; Wright JJ
Clin Cancer Res; 2000 Sep; 6(9):3522-9. PubMed ID: 10999739
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the DNA-binding and transcriptional repression activity of the Wilms' tumor gene product, WT1, by cAMP-dependent protein kinase-mediated phosphorylation of Ser-365 and Ser-393 in the zinc finger domain.
Sakamoto Y; Yoshida M; Semba K; Hunter T
Oncogene; 1997 Oct; 15(17):2001-12. PubMed ID: 9366517
[TBL] [Abstract][Full Text] [Related]
19. Repression of the transforming growth factor-beta 1 gene by the Wilms' tumor suppressor WT1 gene product.
Dey BR; Sukhatme VP; Roberts AB; Sporn MB; Rauscher FJ; Kim SJ
Mol Endocrinol; 1994 May; 8(5):595-602. PubMed ID: 8058069
[TBL] [Abstract][Full Text] [Related]
20. Transcription factor EGR-1 suppresses the growth and transformation of human HT-1080 fibrosarcoma cells by induction of transforming growth factor beta 1.
Liu C; Adamson E; Mercola D
Proc Natl Acad Sci U S A; 1996 Oct; 93(21):11831-6. PubMed ID: 8876223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
